C12Y 304/24024
Gelatinase a , i.e. matrix metalloproteinase 2 or mmp2
Official title: Gelatinase A (3.4.24.24), i.e. matrix metalloproteinase 2 or MMP2
C12Y304/24024 (Gelatinase a , i.e. matrix metalloproteinase 2 or mmp2) appears on 12 US grants and 24 published applications in this corpus.
Search patents in C12Y- Granted patents
- 12
- Published applications
- 24
- Assignees
- 16
- Inventors
- 44
- Latest grant
- 5 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2013 | 0 | 1 |
| 2014 | 0 | 1 |
| 2015 | 0 | 0 |
| 2016 | 0 | 3 |
| 2017 | 1 | 1 |
| 2018 | 2 | 1 |
| 2019 | 0 | 4 |
| 2020 | 0 | 1 |
| 2021 | 0 | 2 |
| 2022 | 1 | 0 |
| 2023 | 3 | 4 |
| 2024 | 3 | 1 |
| 2025 | 1 | 2 |
| 2026 | 1 | 3 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Protease-cleavable substrates and methods of use thereof5 May 2026US 12,617,856 B2CytomX Therapeutics, Inc.
- Peptides and conjugates7 Jan 2025US 12,188,065 B2The University of Liverpool
- Autophagy as a therapeutic target for intracranial aneurysm15 Oct 2024US 12,116,597 B2Board of Regents, The University of Texas System
- Fusion protein construct24 Sep 2024US 12,098,215 B2Northwestern University
- Fibrosis-inhibiting composition, cells producing same, and cell sheet comprising said cells9 Jan 2024US 11,866,483 B2KanonCure, Inc.
- RNA-Based Compositions and Methods for Treating Breast Cancer24 Sep 2026US 2026/0286354 A1Avicenna Biotech Research, LLC
- Protease-cleavable moieties and methods of use thereof19 Feb 2026US 2026/0049148 A1CytomX Therapeutics, Inc.
- Protease-cleavable moieties and methods of use thereof12 Feb 2026US 2026/0042849 A1CytomX Therapeutics, Inc.
- Protease-cleavable substrates and methods of use thereof3 Jul 2025US 2025/0215095 A1CytomX Therapeutics, Inc.
- Fusion Protein Construct20 Feb 2025US 2025/0059301 A1Northwestern University
Most cited
By later US patents